CTLA4 and posterior cortical atrophy: Notably, patients with high SLAMF8 expression who are single-positive for PD1 or CTLA4, or double-negative or double-positive for both markers, exhibit elevated immunotherapy scores, hinting at the potential for immunotherapy to benefit this subgroup of PCa patients (Fig. 7Q-T).